Alterations in mitochondrial function as a harbinger of cardiomyopathy: Lessons from the dystrophic heart

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 2, 2010, Pages 310-321

  Burelle, Yan ^a   Khairallah, Maya ^a,b   Ascah, Alexis ^a   Allen, Bruce G ^a,b   Deschepper, Christian F ^c   Petrof, Basil J ^d   Des Rosiers, Christine ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cardioprotection; Cyclic GMP signalling; Duchenne muscular dystrophy; Energy substrate metabolism; Mitochondrial transition pore

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CALCIUM; CYCLIC GMP; CYCLOPHILIN A; CYCLOPHILIN D; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYTOSKELETON PROTEIN; DYSTROPHIN; IDEBENONE; MITO Q; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; SANGLIFEHRIN A; SELENIUM; SILDENAFIL; SNT MC 17; TADALAFIL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CELL DEATH; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG PROTEIN BINDING; DUCHENNE MUSCULAR DYSTROPHY; ENERGY METABOLISM; HEART CONTRACTION; HEART FAILURE; HEART MITOCHONDRION; HUMAN; MITOCHONDRIAL MEMBRANE; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 74149088716     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.09.004     Document Type: Review

References (167)

1. Huss J.M., and Kelly D.P. Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Invest. 115 (2005) 547-555
2. Marin-Garcia J., and Goldenthal M.J. Mitochondrial centrality in heart failure. Heart Fail. Rev. 13 2 (2008) 137-150
3. Murray A.J., Edwards L.M., and Clarke K. Mitochondria and heart failure. Curr. Opin. Clin. Nutr. Metab. Care 10 (2007) 704-711
4. Tsutsui H., Kinugawa S., and Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc. Res. 81 (2009) 449-456
5. Ventura-Clapier R., Garnier A., and Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc. Res. 79 (2008) 208-217
6. Lemieux H., and Hoppel C.L. Mitochondria in the human heart. J. Bioenerg. Biomembr. 41 (2009) 99-106
7. Rosca M.G., Vazquez E.J., Kerner J., Parland W., Chandler M.P., Stanley W., et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc. Res. 80 (2008) 30-39
8. Khairallah M., Khairallah R., Young M.E., Dyck J.R., Petrof B.J., and Des Rosiers C. Metabolic and signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J. Mol. Cell. Cardiol. 43 (2007) 119-129
9. Khairallah M., Khairallah R.J., Young M.E., Allen B.G., Gillis M.A., Danialou G., et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 7028-7033
10. Badorff C., Lee G.H., Lamphear B.J., Martone M.E., Campbell K.P., Rhoads R.E., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5 (1999) 320-326
11. Rodriguez M., Cai W.J., Kostin S., Lucchesi B.R., and Schaper J. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J. Mol. Cell. Cardiol. 38 (2005) 723-733
12. Vatta M., Stetson S.J., Perez-Verdia A., Entman M.L., Noon G.P., Torre-Amione G., et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359 (2002) 936-941
13. Wallace G.Q., and McNally E.M. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu. Rev. Physiol. 71 (2009) 37-57
14. Towbin J.A., and Bowles N.E. The failing heart. Nature 415 (2002) 227-233
15. Goodwin F.C., and Muntoni F. Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 32 (2005) 577-588
16. Nigro G., Comi L.I., Limongelli F.M., Giugliano M.A., Politano L., Petretta V., et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 6 (1983) 253-262
17. Nigro G., Comi L.I., Politano L., and Bain R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26 (1990) 271-277
18. Cox G.F., and Kunkel L.M. Dystrophies and heart disease. Curr. Opin. Cardiol. 12 (1997) 329-343
19. Hainsey T.A., Senapati S., Kuhn D.E., and Rafael J.A. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscular Disord. 13 (2003) 294-302
20. Zhu X., Wheeler M.T., Hadhazy M., Lam M.Y., and McNally E.M. Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J. 16 (2002) 1096-1098
21. de Kermadec J.M., Becane H.M., Chenard A., Tertrain F., and Weiss Y. Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: an echocardiographic study. Am. Heart J. 127 (1994) 618-623
22. Mukoyama M., Kondo K., Hizawa K., and Nishitani H. Life spans of Duchenne muscular dystrophy patients in the hospital care program in Japan. J. Neurol. Sci. 81 (1987) 155-158
23. Quinlan J.G., Hahn H.S., Wong B.L., Lorenz J.N., Wenisch A.S., and Levin L.S. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul. Disord. 14 (2004) 491-496
24. Bia B.L., Cassidy P.J., Young M.E., Rafael J.A., Leighton B., Davies K.E., et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J. Mol. Cell. Cardiol. 31 (1999) 1857-1862
25. Wilding J.R., Schneider J.E., Sang A.E., Davies K.E., Neubauer S., and Clarke K. Dystrophin-and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J. 19 (2005) 79-81
26. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., and Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 3710-3714
27. Danialou G., Comtois A.S., Dudley R., Karpati G., Vincent G., Des Rosiers C., et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15 (2001) 1655-1657
28. Kamogawa Y., Biro S., Maeda M., Setoguchi M., Hirakawa T., Yoshida H., et al. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. Cardiovasc. Res. 50 (2001) 509-515
29. Nakamura A., Yoshida K., Takeda S., Dohi N., and Ikeda S. Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise in hearts of mdx mice. FEBS Lett. 520 (2002) 18-24
30. Petrof B.J. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol. Cell. Biochem. 179 (1998) 111-123
31. Petrof B.J. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am. J. Phys. Med. Rehabil. 81 (2002) S162-S174
32. Oceandy D., Cartwright E.J., Emerson M., Prehar S., Baudoin F.M., Zi M., et al. Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation 115 (2007) 483-492
33. Kanai A.J., Pearce L.L., Clemens P.R., Birder L.A., VanBibber M.M., Choi S.Y., et al. Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 14126-14131
34. Bendall J.K., Damy T., Ratajczak P., Loyer X., Monceau V., Marty I., et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110 (2004) 2368-2375
35. Ashrafian H., Frenneaux M.P., and Opie L.H. Metabolic mechanisms in heart failure. Circulation 116 (2007) 434-448
36. Neubauer S. The failing heart-an engine out of fuel. N. Engl. J. Med. 356 (2007) 1140-1151
37. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005) 1093-1129
38. van Bilsen M., van Nieuwenhoven F.A., and van der Vusse G.J. Metabolic remodelling of the failing heart: beneficial or detrimental?. Cardiovasc. Res. 81 (2009) 420-428
39. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 81 (2009) 412-419
40. Chandler M.P., Kerner J., Huang H., Vazquez E., Reszko A., Martini W.Z., et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1538-H1543
41. de Brouwer K.F., Degens H., Aartsen W.M., Lindhout M., Bitsch N.J., Gilde A.J., et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J. Mol. Cell. Cardiol. 40 (2006) 838-845
42. Borradaile N.M., and Schaffer J.E. Lipotoxicity in the heart. Curr. Hypertens. Rep. 7 (2005) 412-417
43. Gélinas R., Labarthe F., Bouchard B., Mc D.J., Charron G., Young M.E., et al. Alterations in carbohydrate metabolism and its regulation in PPARalpha null mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1571-H1580
44. Labarthe F., Khairallah M., Bouchard B., Stanley W.C., and Des Rosiers C. Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1425-H1436
45. Lewin T.M., and Coleman R.A. Regulation of myocardial triacylglycerol synthesis and metabolism. Biochim. Biophys. Acta 1634 (2003) 63-75
46. Russell L.K., Finck B.N., and Kelly D.P. Mouse models of mitochondrial dysfunction and heart failure. J. Mol. Cell. Cardiol. 38 (2005) 81-91
47. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB. J. 18 (2004) 1692-1700
48. Bueno O.F., Wilkins B.J., Tymitz K.M., Glascock B.J., Kimball T.F., Lorenz J.N., et al. Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 4586-4591
49. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 907-912
50. Khairallah R.J., Khairallah M., Gelinas R., Bouchard B., Young M.E., Allen B.G., et al. Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation. J. Mol. Cell. Cardiol. 45 (2008) 230-239
51. Allard M.F., Wambolt R.B., Longnus S.L., Grist M., Lydell C.P., Parsons H.L., et al. Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E487-E493
52. Nascimben L., Ingwall J.S., Lorell B.H., Pinz I., Schultz V., Tornheim K., et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44 (2004) 662-667
53. Sambandam N., Lopaschuk G.D., Brownsey R.W., and Allard M.F. Energy metabolism in the hypertrophied heart. Heart Fail. Rev. 7 (2002) 161-173
54. Haemmerle G., Lass A., Zimmermann R., Gorkiewicz G., Meyer C., Rozman J., et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312 (2006) 734-737
55. Yamashita H., Bharadwaj K.G., Ikeda S., Park T.S., and Goldberg I.J. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E705-E713
56. Khairallah M., Labarthe F., Bouchard B., Danialou G., Petrof B.J., and Des Rosiers C. Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1461-H1470
57. Momose M., Iguchi N., Imamura K., Usui H., Ueda T., Miyamoto K., et al. Depressed myocardial fatty acid metabolism in patients with muscular dystrophy. Neuromuscul. Disord. 11 (2001) 464-469
58. Naruse H., Miyagi J., Arii T., Ohyanagi M., Iwasaki T., and Jinnai K. The relationship between clinical stage, prognosis and myocardial damage in patients with Duchenne-type muscular dystrophy: five-year follow-up study. Ann. Nucl. Med. 18 (2004) 203-208
59. Perloff J.K., Henze E., and Schelbert H.R. Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation 69 (1984) 33-42
60. Quinlivan R.M., Lewis P., Marsden P., Dundas R., Robb S.A., Baker E., et al. Cardiac function, metabolism and perfusion in Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 6 (1996) 237-246
61. Matsui T., and Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J. Mol. Cell. Cardiol. 38 (2005) 63-71
62. Young L.H., Li J., Baron S.J., and Russell R.R. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc. Med. 15 (2005) 110-118
63. Barger P.M., Browning A.C., and Garner A.N. Kelly DP. p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J. Biol. Chem. 276 (2001) 44495-44501
64. Krumenacker J.S., Hanafy K.A., and Murad F. Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res. Bull. 62 (2004) 505-515
65. Nishikimi T., Maeda N., and Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc. Res. 69 (2006) 318-328
66. Heydemann A., Huber J.M., Kakkar R., Wheeler M.T., and McNally E.M. Functional nitric oxide synthase mislocalization in cardiomyopathy. J. Mol. Cell. Cardiol. 36 (2004) 213-223
67. Wehling-Henricks M., Jordan M.C., Roos K.P., Deng B., and Tidball J.G. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 14 (2005) 1921-1933
68. Paulus W.J., and Bronzwaer J.G. Nitric oxide's role in the heart: control of beating or breathing?. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H8-13
69. Recchia F.A. Role of nitric oxide in the regulation of substrate metabolism in heart failure. Heart Fail. Rev. 7 (2002) 141-148
70. Henning S.L., Wambolt R.B., Schonekess B.O., Lopaschuk G.D., and Allard M.F. Contribution of glycogen to aerobic myocardial glucose utilization. Circulation 93 (1996) 1549-1555
71. Lewandowski E.D. Metabolic heterogeneity of carbon substrate utilization in mammalian heart: NMR determinations of mitochondrial versus cytosolic compartmentation. Biochemistry 31 (1992) 8916-8923
72. Schonekess B.O., Brindley P.G., and Lopaschuk G.D. Calcium regulation of glycolysis, glucose oxidation, and fatty acid oxidation in the aerobic and ischemic heart. Can. J. Physiol. Pharmacol. 73 (1995) 1632-1640
73. Chen Y.W., Zhao P., Borup R., and Hoffman E.P. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J. Cell. Biol. 151 (2000) 1321-1336
74. Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr. Opin. Genet. Dev. 18 (2008) 426-434
75. Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., and Spiegelman B.M. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 21 (2007) 770-783
76. Zhang W., ten Hove M., Schneider J.E., Stuckey D.J., Sebag-Montefiore L., Bia B.L., et al. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: an MRI and MRS study. J. Mol. Cell. Cardiol. 45 (2008) 754-760
77. Duchen M.R. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J. Physiol. 516 Pt 1 (1999 Apr 1) 1-17
78. Ichas F., Jouaville L.S., and Mazat J.P. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell 89 (1997) 1145-1153
79. Ichas F., Jouaville L.S., Sidash S.S., Mazat J.P., and Holmuhamedov E.L. Mitochondrial calcium spiking: a transduction mechanism based on calcium-induced permeability transition involved in cell calcium signalling. FEBS Lett. 348 (1994) 211-215
80. Ichas F., and Mazat J.P. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low-to high-conductance state. Biochim. Biophys. Acta 1366 (1998) 33-50
81. Cadenas E., Poderoso J.J., Antunes F., and Boveris A. Analysis of the pathways of nitric oxide utilization in mitochondria. Free Radic. Res. 33 (2000) 747-756
82. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 52 (2001) 159-164
83. Poderoso J.J., Boveris A., and Cadenas E. Mitochondrial oxidative stress: a self-propagating process with implications for signaling cascades. Biofactors 11 (2000) 43-45
84. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003) 335-344
85. Green D.R. Apoptotic pathways: the roads to ruin. Cell 94 (1998) 695-698
86. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
87. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
88. Mattson M.P., and Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9 (2003) 196-205
89. Waterhouse N.J., Ricci J.E., and Green D.R. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 84 (2002) 113-121
90. Zoratti M., Szabo I., and De Marchi U. Mitochondrial permeability transitions: how many doors to the house?. Biochim. Biophys. Acta 1706 (2005) 40-52
91. Ozcan C., Bienengraeber M., Hodgson D.M., Mann D.L., and Terzic A. Mitochondrial tolerance to stress impaired in failing heart. J. Mol. Cell. Cardiol. 35 (2003) 1161-1166
92. Sabbah H.N., Sharov V., Riddle J.M., Kono T., Lesch M., and Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J. Mol. Cell. Cardiol. 24 (1992) 1333-1347
93. Buchwald A., Till H., Unterberg C., Oberschmidt R., Figulla H.R., and Wiegand V. Alterations of the mitochondrial respiratory chain in human dilated cardiomyopathy. Eur. Heart J. 11 (1990) 509-516
94. Ide T., Tsutsui H., Hayashidani S., Kang D., Suematsu N., Nakamura K., et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ. Res. 88 (2001) 529-535
95. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85 (1999) 357-363
96. Jarreta D., Orus J., Barrientos A., Miro O., Roig E., Heras M., et al. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc. Res. 45 (2000) 860-865
97. Javadov S., Huang C., Kirshenbaum L., and Karmazyn M. NHE-1 inhibition improves impaired mitochondrial permeability transition and respiratory function during postinfarction remodelling in the rat. J. Mol. Cell. Cardiol. 38 (2005) 135-143
98. Moe G.W., Marin-Garcia J., Konig A., Goldenthal M., Lu X., and Feng Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1813-H1820
99. Scheubel R.J., Tostlebe M., Simm A., Rohrbach S., Prondzinsky R., Gellerich F.N., et al. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J. Am. Coll. Cardiol. 40 (2002) 2174-2181
100. Sharov V.G., Todor A.V., Silverman N., Goldstein S., and Sabbah H.N. Abnormal mitochondrial respiration in failed human myocardium. J. Mol. Cell. Cardiol. 32 (2000) 2361-2367
101. Sordahl L.A., McCollum W.B., Wood W.G., and Schwartz A. Mitochondria and sarcoplasmic reticulum function in cardiac hypertrophy and failure. Am. J. Physiol. 224 (1973) 497-502
102. Guarnieri C., Muscari C., and Caldarera C.M. Oxygen radicals and tissue damage in heart hypertrophy. Adv. Myocardiol. 5 (1985) 191-199
103. Kobayashi A., Yamashita T., Kaneko M., Nishiyama T., Hayashi H., and Yamazaki N. Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster. J. Am. Coll. Cardiol. 10 (1987) 1128-1138
104. Marin-Garcia J., Goldenthal M.J., Pierpont E.M., Ananthakrishnan R., and Perez-Atayde A. Is age a contributory factor of mitochondrial bioenergetic decline and DNA defects in idiopathic dilated cardiomyopathy?. Cardiovasc. Pathol. 8 (1999) 217-222
105. Matsushima S., Ide T., Yamato M., Matsusaka H., Hattori F., Ikeuchi M., et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113 (2006) 1779-1786
106. Moe G.W., Naik G., Konig A., Lu X., and Feng Q. Early and persistent activation of myocardial apoptosis, bax and caspases: insights into mechanisms of progression of heart failure. Pathophysiology 8 (2002) 183-192
107. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336 (1997) 1131-1141
108. Saraste A., Pulkki K., Kallajoki M., Heikkila P., Laine P., Mattila S., et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur. J. Clin. Invest. 29 (1999) 380-386
109. Sharov V.G., Todor A., Khanal S., Imai M., and Sabbah H.N. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J. Mol. Cell. Cardiol. 42 (2007) 150-158
110. Narula J., Pandey P., Arbustini E., Haider N., Narula N., Kolodgie F.D., et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8144-8149
111. Scheubel R.J., Bartling B., Simm A., Silber R.E., Drogaris K., Darmer D., et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival?. J. Am. Coll. Cardiol. 39 (2002) 481-488
112. Crow M.T., Mani K., Nam Y.J., and Kitsis R.N. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ. Res. 95 (2004) 957-970
113. Marcil M., Ascah A., Matas J., Belanger S., Deschepper C.F., and Burelle Y. Compensated volume overload increases the vulnerability of heart mitochondria without affecting their functions in the absence of stress. J. Mol. Cell. Cardiol. 41 (2006) 998-1009
114. Matas J., Young N.T., Bourcier-Lucas C., Ascah A., Marcil M., Deschepper C.F., et al. Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J. Mol. Cell. Cardiol. 46 (2009) 420-430
115. Kang P.M., Yue P., Liu Z., Tarnavski O., Bodyak N., and Izumo S. Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H72-H80
116. Allard M.F., Flint J.D., English J.C., Henning S.L., Salamanca M.C., Kamimura C.T., et al. Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J. Mol. Cell. Cardiol. 26 (1994) 1551-1563
117. Anderson P.G., Allard M.F., Thomas G.D., Bishop S.P., and Digerness S.B. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ. Res. 67 (1990) 948-959
118. Gaasch W.H., Zile M.R., Hoshino P.K., Weinberg E.O., Rhodes D.R., and Apstein C.S. Tolerance of the hypertrophic heart to ischemia. Studies in compensated and failing dog hearts with pressure overload hypertrophy. Circulation 81 (1990) 1644-1653
119. Ciminelli M., Ascah A., Bourduas K., and Burelle Y. Short term training attenuates opening of the mitochondrial permeability transition pore without affecting myocardial function following ischemia-reperfusion. Mol. Cell. Biochem. 291 (2006) 39-47
120. Griffiths E.J., and Halestrap A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem. J. 307 (1995) 93-98
121. Millay D.P., Sargent M.A., Osinska H., Baines C.P., Barton E.R., Vuagniaux G., et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat. Med. 14 (2008) 442-447
122. Hicks D., Lampe A.K., Laval S.H., Allamand V., Jimenez-Mallebrera C., Walter M.C., et al. Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain 132 (2009) 147-155
123. Angelin A., Tiepolo T., Sabatelli P., Grumati P., Bergamin N., Golfieri C., et al. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 991-996
124. Reutenauer J., Dorchies O.M., Patthey-Vuadens O., Vuagniaux G., and Ruegg U.T. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br. J. Pharmacol. 155 (2008) 574-584
125. Gnecchi-Ruscone T., Taylor J., Mercuri E., Paternostro G., Pogue R., Bushby K., et al. Cardiomyopathy in duchenne, becker, and sarcoglycanopathies: a role for coronary dysfunction?. Muscle Nerve 22 (1999) 1549-1556
126. Mendell J.R., Engel W.K., and Derrer E.C. Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 172 (1971) 1143-1145
127. Zoratti M., and Szabo I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1241 (1995) 139-176
128. Gailly P. New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim. Biophys. Acta 1600 (2002) 38-44
129. Williams I.A., and Allen D.G. Intracellular calcium handling in ventricular myocytes from mdx mice. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H846-H855
130. 2+ loading in neonatal rabbit cardiac ventricular myocytes. Am. J. Physiol. Cell. Physiol. 290 (2006) C1572-C1582
131. Robert V., Massimino M.L., Tosello V., Marsault R., Cantini M., Sorrentino V., et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J. Biol. Chem. 276 (2001) 4647-4651
132. Vandebrouck A., Ducret T., Basset O., Sebille S., Raymond G., Ruegg U., et al. Regulation of store-operated calcium entries and mitochondrial uptake by minidystrophin expression in cultured myotubes. FASEB J. 20 (2006) 136-138
133. Bellinger A.M., Reiken S., Carlson C., Mongillo M., Liu X., Rothman L., et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15 (2009) 325-330
134. 2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 262 (1993) 744-747
135. Robert V., Gurlini P., Tosello V., Nagai T., Miyawaki A., Di Lisa F., et al. Beat-to-beat oscillations of mitochondrial [Ca2+] in cardiac cells. EMBO J. 20 (2001) 4998-5007
136. 2+ current I(CRAC). EMBO J. 19 (2000) 6401-6407
137. Dudley R.W., Khairallah M., Mohammed S., Lands L., Des Rosiers C., and Petrof B.J. Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R704-R710
138. Kuznetsov A.V., Winkler K., Wiedemann F.R., von Bossanyi P., Dietzmann K., and Kunz W.S. Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. Mol. Cell. Biochem. 183 (1998) 87-96
139. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 (2005) 1601-1610
140. Ockaili R., Salloum F., Hawkins J., and Kukreja R.C. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1263-H1269
141. Salloum F., Yin C., Xi L., and Kukreja R.C. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. 92 (2003) 595-597
142. Costa A.D., Garlid K.D., West I.C., Lincoln T.M., Downey J.M., Cohen M.V., et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ. Res. 97 (2005) 329-336
143. Costa A.D., Quinlan C.L., Andrukhiv A., West I.C., Jaburek M., and Garlid K.D. The direct physiological effects of mitoK(ATP) opening on heart mitochondria. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H406-H415
144. Das A., Salloum F.N., Xi L., Rao Y.J., and Kukreja R.C. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H1236-H1243
145. Mendelsohn M.E. Viagra: now mending hearts. Nat. Med. 11 (2005) 115-116
146. Schlossmann J., Feil R., and Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Ann. Med. 35 (2003) 21-27
147. Yue Y., Li Z., Harper S.Q., Davisson R.L., Chamberlain J.S., and Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108 (2003) 1626-1632
148. Perkins K.J., and Davies K.E. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul. Disord. 12 Suppl. 1 (2002) S78-S89
149. Deconinck A.E., Rafael J.A., Skinner J.A., Brown S.C., Potter A.C., Metzinger L., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90 (1997) 717-727
150. Janssen P.M., Hiranandani N., Mays T.A., and Rafael-Fortney J.A. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2373-H2378
151. McNally E.M. New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu. Rev. Med. 58 (2007) 75-88
152. 2+signalling and reactive oxygen species-generating pathways. Cardiovasc. Res. 77 (2008 Mar 1) 766-773
153. Connern C.P., and Halestrap A.P. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem. J. 302 (1994) 321-324
154. 2+]. Biochemistry 35 (1996) 8172-8180
155. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341 (1999) 233-249
156. Halestrap A.P., Clarke S.J., and Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res. 61 (2004) 372-385
157. Morioka M., Hamada J., Ushio Y., and Miyamoto E. Potential role of calcineurin for brain ischemia and traumatic injury. Prog. Neurobiol. 58 (1999) 1-30
158. Nishinaka Y., Sugiyama S., Yokota M., Saito H., and Ozawa T. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. J. Cardiovasc. Pharmacol. 21 (1993) 448-454
159. Ruiz F., Alvarez G., Ramos M., Hernandez M., Bogonez E., and Satrustegui J. Cyclosporin A targets involved in protection against glutamate excitotoxicity. Eur. J. Pharmacol. 404 (2000) 29-39
160. Backman E., Nylander E., Johansson I., Henriksson K.G., and Tagesson C. Selenium and vitamin E treatment of Duchenne muscular dystrophy: no effect on muscle function. Acta Neurol. Scand. 78 (1988) 429-435
161. Tidball J.G., and Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J. Appl. Physiol. 102 (2007) 1677-1686
162. Buyse G.M., Van der Mieren G., Erb M., D'Hooge J., Herijgers P., Verbeken E., et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur. Heart J. 30 (2009) 116-124
163. Adlam V.J., Harrison J.C., Porteous C.M., James A.M., Smith R.A., Murphy M.P., et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 19 9 (2005) 1088-1095
164. Jauslin M.L., Meier T., Smith R.A., and Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17 (2003) 1972-1974
165. Parchen M.C., Percival J.M., Dao-Fu D., Gray H.N., Frohner S.C., and Beavo J.A. Sildenafil Ameliorates Cardiomyopathy in mdx Mice. FASEB J. 23 (2009) (abstract #823.1)
166. Asai A., Sahani N., Kaneki M., Ouchi Y., Martyn J.A., and Yasuhara S.E. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE e806 (2007) 2
167. Kyoi S., Otani H., Hamano A., Matsuhisa S., Akita Y., Fujiwara H., et al. Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion. Cardiovasc. Res. 70 (2006) 354-363